Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671356 | 0.84 | CYP19A1 (0.45) | CYP19A1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL28423412 | 0.77 | KCNN4 (0.38) | CYP19A1MEN1KMT2AMAPK1 | |
| SCHEMBL308187 | 0.75 | KIF11 (0.50) | MEN1KMT2ATSHRMAPK1HIF1A | |
| SCHEMBL306439 | 0.75 | ESR1 (0.58) | MEN1KMT2ATSHRHIF1ALMNA | |
| SCHEMBL608968 | 0.74 | ESR1 (0.56) | CYP19A1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL516478 | 0.74 | TSHR (0.52) | TSHRMAPK1 | |
| SCHEMBL5350641 | 0.74 | CYP19A1 (0.45) | CYP19A1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL5238555 | 0.74 | CYP19A1 (0.45) | CYP19A1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL809832 | 0.73 | LMNA (0.50) | CYP19A1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL196588 | 0.73 | CYP19A1 (0.55) | CYP19A1MEN1KMT2ATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111302944-B | Preparation method of bis (3-amino-4-hydroxyphenyl) hexafluoropropane | 上海如鲲新材料有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-111302944-A | Preparation method of bis (3-amino-4-hydroxyphenyl) hexafluoropropane | 上海如鲲新材料有限公司 | 2020-06-19 | — | — | CN | disclosed |
| EP-2438106-B1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | BOEING CO (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2438106-A1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | The Boeing Company (US) | 2012-04-11 | — | — | EP | disclosed |
| US-8106142-B2 | Polyacetylinic oligomers | THE BOEING COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8063168-B2 | Oligomers with di-phenylethynyl endcaps | THE BOEING COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010141106-A1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | THE BOEING COMPANY (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100204485-A1 | POLYACETYLINIC OLIGOMERS | THE BOEING COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-20100204412-A1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | THE BOEING COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-5071941-A | Multidimensional ether sulfone oligomers | THE BOEING COMPANY (US) | 1991-12-10 | — | — | US | disclosed |
| US-4851501-A | Polyethersulfone prepregs, composites, and blends | THE BOEING COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| US-4739030-A | Difunctional end-cap monomers | THE BOEING COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| US-4536559-A | Thermally stable polyimide polysulfone compositions for composite structures | THE BOEING COMPANY (US) | 1985-08-20 | — | — | US | disclosed |
| US-4476184-A | CURABLE THERMOPLASTIC PREPRESS, OXYNADIMIDE SUBSTITUENTS | THE BOEING COMPANY (US) | 1984-10-09 | — | — | US | disclosed |
| US-4414269-A | CONTAINING CONDENSATION PRODUCT OF AMINO-PHENOL AND ACID ANHYDRIDE, AN AROMATIC POLYOL, AND AROMATIC DIHALIDE | TRW, INC. (US) | 1983-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204485-A1 | POLYACETYLINIC OLIGOMERS | AADAC, ACMSD, ECPAS | CYP19A1 4671/4885MEN1 4503/4885KMT2A 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.